Navigation Links
Neurobiological Technologies, Inc. Reports Fourth Quarter and Fiscal Year-End Financial Results for 2007 Announces 1-for-7 Reverse Stock Split
Date:9/14/2007

it share certificates and receive new post-split certificates.

Conference Call Information

NTI will web cast its year end financial results conference call on September 17, 2007 at 10:30 a.m. ET, 7:30 a.m. PT. Dial-in number 800-289-0468 (U.S.) 913-981-5517 (international). The live web cast can be accessed by going to http://www.shareholder.com/ntii/medialist.cfm. Playback of the conference call will be available from 1:30 p.m. ET on September 17, 2007 through 11:59 p.m. on September 21, 2007. Replay number: 888-203-1112 (US and Canada) and 719-457-0820 (International), replay access code: 9278405.

About Neurobiological Technologies, Inc.

NTI is a specialty biopharmaceutical company with expertise in identifying and acquiring promising drug candidates and in designing and managing late-stage clinical trials for central nervous system conditions. NTI is currently developing Viprinex, a novel reperfusion agent that is in pivotal Phase 3 trials for the treatment of acute ischemic stroke.

NOTE: Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including: our need for additional capital, our dependence on third parties for the development, regulatory approval and successful commercialization of our products, the inherent risk of failure in developing product candidates based on new technologies, the risks associated with the cost of clinical development efforts, and other risks detailed from time to time in our Annual Report of Form 10-K and other filings with the Securities and Exchange Commission. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release. We disclaim, however, any intent or obligation to update these forward-looking statements.


'/>"/>

SOURCE Neurobiological Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... July 28, 2015 CSL Behring ... has accepted for review the company,s Biologics License Application ... (rVIII-SingleChain) for the treatment of hemophilia A. In the ... Hemophilia A is a congenital ... nearly all affected patients are male. People with hemophilia ...
(Date:7/28/2015)... Israel , July 28, 2015 ... medicine company utilizing its proprietary plant-based rhCollagen technology ... Shurtz has been appointed Senior Director of Business ... (Photo: http://photos.prnewswire.com/prnh/20150728/246955 ) , ... in marketing, regulatory and business strategy. Prior to ...
(Date:7/27/2015)... FRANKLIN, Tenn. , July 27, 2015 /PRNewswire/ ... health care services and one of the largest ... that its parent company and sole stockholder, Capella ... Medical Properties Trust, Inc. ("MPT") (NYSE: MPW ... cash.  The transaction is expected to be finalized ...
(Date:7/27/2015)... London, UK (PRWEB) , ... July 27, 2015 , ... ... stable growth over the past few years in the EU. For instance, it surpassed ... approximately the EUR 92 million mark in 2010. Germany is a major producer, while ...
Breaking Biology Technology:U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3CollPlant Names Shomrat Shurtz Senior Director of Business Development 2Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 2Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 3Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 4Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 5High Tenacity Filament Yarn of Viscose Rayon Consumption to Grow Swiftly in the EU, Forecasts BAC Reports in New Study Available at MarketPublishers.com 2
... Pharmaceuticals, Inc.,(Nasdaq: SGXP ) will be presenting at ... BioCentury and Thomson on Thursday, March 27,2008 at 9:00 ... officer of SGX Pharmaceuticals, will provide an overview of ... the Millennium,Broadway Hotel and Conference Center in New York ...
... and policy makers have drawn up a list of the ... in the UK between now and 2050. As well as ... shows how "horizon scanning" could help us foresee issues that ... past, such as the UK public,s response to genetically modified ...
... 19 Genomas(R), a,biomedical company advancing DNA-guided medicine ... Fast-Track Phase I-II Small,Business Innovation Research (SBIR) Grant ... for Statin Safety and Efficacy," was,awarded by the ... Statins are the most prescribed drugs in the ...
Cached Biology Technology:Genomas Awarded $1.2 Million NIH SBIR Grant to Develop DNA-Guided System for Management of Statin Therapy 2
(Date:7/9/2015)... July 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), ... that it will report financial results for the fourth ... 2015 after the close of market. The company will ... at 2:00 p.m. PT (5:00 p.m. ET), during which ... participate on the live call, analysts and investors should ...
(Date:7/8/2015)... LAKES , N.J. and NEW YORK ... Company) and Guidepoint today announced BD ... start-up healthcare companies with free access to Guidepoint,s expert ... several start-ups that are developing cutting-edge technologies to improve ... a dedicated Guidepoint research manager, each start-up entrepreneur will ...
(Date:7/7/2015)... , July 7, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... the growing mobile commerce market announces a revised version of one ... The commercial will air on CNBC in New York ... and San Francisco metro areas. ... focuses on Wocket,s ability to replace all the cards in your ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3
... gypsy moth, a highly destructive insect that has damaged millions ... spread throughout the country despite the use of safer, more ... Engineering News ( C&EN ), ACS, weekly newsmagazine. ... gypsy moth has been plaguing the Northeastern United States and ...
... R.I. [Brown University] Scientists have long known that ... clear is how the brain processes more complex and ... 28, 2010) in the journal Neuron , a ... of CaliforniaBerkeley tested whether the frontal lobe has the ...
... A new study using high speed video and feathers bought ... his outer tail feathers, they flutter like flags in the wind, ... to increase the speed and therefore raise the pitch of the ... The acoustic communication of birds has been widely researched as ...
Cached Biology News:Complex brain functions help adapt to new situations and stimuli 2Flag has ladies all of a flutter 2
Anti-Mouse Qa.m8, Ascites (Clone 5035-24.1) (mouse IgG3)...
... and TriEx Insect Cell Medium are recommended ... This cell/medium combination has been selected based ... protein expression levels observed specifically with baculoviruses ... that our Ready-Plaque Sf9 Cells and BacVector ...
...
...
Biology Products: